Abstract
The spread of COVID-19 is posing an unprecedented threat to health systems worldwide1. The fast propagation of the disease combined with the existence of covert contagions by asymptomatic individuals make the controlling of this disease particularly challenging. The key parameter to track the progression of the epidemics is the effective reproduction number ℛ, defined as the number of secondary infections generated by an infected individual2. The suppression of the epidemics is directly related to this value, and is attained when ℛ < 1. Here, we find an analytical expression for ℛ as a function of mobility restrictions and confinement measures, using an epidemic model tailored for COVID-19. This expression for ℛ is an extremely useful tool to design containment policies that are able to suppress the epidemics. We applied our epidemic model for the case of Spain, successfully forecasting both the observed incidence in each region and the overload of the health system. The expression for ℛ allowed us to determine the precise reduction of mobility κ0 needed to bend the curve of epidemic incidence, which turned out to be κ0 ∼ 0.7. This value, for the case of Spain, translates to a total lockdown with the exception of the mobility associated to essential services, a policy that was finally enforced on March 28.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Spanish MINECO (grant PGC2018-094754-B-C21, FIS2015-71582-C2 and FIS2017-87519-P), Generalitat de Catalunya (grant No. 2017SGR-896), Universitat Rovira i Virgili (grant No. 2018PFR-URV-B2-41) James S. McDonnell Foundation grant #220020325 Departamento de Industria de Innovación del Gobierno de Aragón y Fondo Social Europeo (FENOL group E-19) Ministerio de Ciencia, Innovación y Universidades (program JdC) Marie Sklodowska-Curie grant agreement No. 713679 Coordenacao de Aperfeicoamento de Pessoal de Nıvel Superior, Brasil (CAPES), Finance Code 001
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code/data is available upon request.
